« Previous | Next » | All Messages |  ZILA Message Board Home | recommend post |  Ignore Poster

ZILA News Zila, Inc. to Release Fiscal 2007 First Quarter Results and Hold Teleconference Regarding Transition to Cancer Detection Company

PHOENIX--(BUSINESS WIRE)--Zila, Inc. (Nasdaq: ZILA) will release financial results for the fiscal 2007 first quarter ended October 31, 2006, at the market close on Thursday, December 7, 2006. The Company will also hold a teleconference to review the Company's financial results and the completion of its transition to a cancer detection company through its recent financing and acquisition of Professional Dental Technologies, Inc. (“Pro-Dentec®”).

Any investor or interested individual can listen to the teleconference, which is scheduled to begin at 1:30 p.m. PST (4:30 p.m. EST) on December 7, 2006. To participate in the teleconference, please call toll-free 877-407-8031 (or 201-689-8031 for international callers) approximately 10 minutes prior to the above start time. You may also listen to the teleconference live via the Internet at www.zila.com. For those unable to attend, the website will host an archive of the call.

A telephone playback will be available for 48 hours beginning at 9:30 p.m. PST on December 7, 2006. The playback can be accessed by calling 877-660-6853 (or 201-612-7415 for international callers) and providing passcode 286 and Conference ID 222192.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is a leading cancer diagnostic company initially focused on oral cancer:

• Zila Pharmaceuticals is dedicated to establishing ViziLite(R) Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer, with initial focus on the dental market through Pro-Dentec(R), a leading designer, manufacturer and marketer of products exclusively to dental professionals for Soft Tissue Management (STM(R)) including the Rota-dent(R) Professional Powered Brush, the Pro-Select3(R) Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM(R) products for both in-office and home-care use.
• Zila Biotechnology is focused on achieving regulatory approval for the next generation oral cancer diagnostic, OraTest(R), followed by the development of additional applications of its cancer detection technologies.

For more information about Zila, visit www.zila.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2006.